• Molecular NameVigabatrin
  • Synonym4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; gamma-Vinyl GABA; GVG; Sabril (TN); Vigabatrin [USAN:BAN:INN]; Vigabatrina [Spanish]; Vigabatrine; Vigabatrine [French]; Vigabatrinum [Latin]
  • Weight129.159
  • Drugbank_IDDB01080
  • ACS_NO60643-86-9
  • Show 3D model
  • LogP (experiment)-2.16
  • LogP (predicted, AB/LogP v2.0)-1.92
  • pka4.02, 9.72
  • LogD (pH=7, predicted)-1.93
  • Solubility (experiment)332 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.48
  • LogSw (predicted, AB/LogsW2.0)392.72
  • Sw (mg/ml) (predicted, ACD/Labs)42.9
  • No.of HBond Donors3
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds4
  • TPSA63.32
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antiepileptic drug that inhibits the catabolism of gamma-Aminobutyric acid (GABA) by irreversibly inhibiting GABA transaminase.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed following oral administration. Food may slightly decrease the rate, but not the extent, of absorption.
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding0.0
  • Volume of distribution (VD)0.8 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAlmost no metabolic transformation occurs
  • Half life5~8 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A